The stock price of Autolus Therapeutics plc ADR (NASDAQ: AUTL) has surged by 4.37% when compared to previous closing price of $2.29, but the company has seen a 3.02% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-12 that Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel LONDON, June 12, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces updated long term data (up to approximately three years of follow up) from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), to be presented in an oral presentation at the European Hematology Association (EHA) Congress between June 12-15, 2025, in Milan, Italy. Autolus will also present an additional oral and poster presentation, the details of which are included below.
Is It Worth Investing in Autolus Therapeutics plc ADR (NASDAQ: AUTL) Right Now?
The stock has a 36-month beta value of 1.89. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AUTL is 240.33M, and at present, short sellers hold a 5.29% of that float. On July 02, 2025, the average trading volume of AUTL was 2.35M shares.
AUTL’s Market Performance
AUTL stock saw an increase of 3.02% in the past week, with a monthly gain of 25.13% and a quarterly increase of 69.50%. The volatility ratio for the week is 5.09%, and the volatility levels for the last 30 days are 6.84% for Autolus Therapeutics plc ADR (AUTL). The simple moving average for the last 20 days is 7.54% for AUTL stock, with a simple moving average of -2.43% for the last 200 days.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Goldman repeating the rating for AUTL by listing it as a “Buy.” The predicted price for AUTL in the upcoming period, according to Goldman is $7.60 based on the research report published on November 18, 2024 of the previous year 2024.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $13. The rating they have provided for AUTL stocks is “Buy” according to the report published on November 15th, 2024.
Deutsche Bank gave a rating of “Buy” to AUTL, setting the target price at $10 in the report published on November 09th of the previous year.
AUTL Trading at 35.46% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.20% of loss for the given period.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -29.73 for the present operating margin
- -2.72 for the gross margin
The net margin for Autolus Therapeutics plc ADR stands at -26.43. The total capital return value is set at -0.39. Equity return is now at value -49.97, with -28.90 for asset returns.
Based on Autolus Therapeutics plc ADR (AUTL), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -4.18. The debt to equity ratio resting at 0.16. The interest coverage ratio of the stock is -8.64.
Currently, EBITDA for the company is -182.42 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 66.51. The receivables turnover for the company is 0.14for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.21.
Conclusion
To sum up, Autolus Therapeutics plc ADR (AUTL) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
